title: Oral hyposensitization to nickel induces clinical improvement and a decrease in TH1 and TH2 cytokines in patients with systemic nickel allergy syndrome.
abstract: Some patients with nickel (Ni) allergic contact dermatitis suffer from systemic (intestinal or cutaneous) symptoms after ingestion of Ni-rich foods and experience symptoms reduction with low-Ni diet, a condition termed Systemic Ni Allergy Syndrome (SNAS). We aimed at evaluating whether oral administration of low nickel doses improved clinical conditions and modulated immunological aspects of SNAS, without significant side effects. Thirty-six SNAS patients were enrolled. Treatment started after 1-month of low-Ni diet and consisted in an incremental oral NiOH dose phase (0.3ng to 1.5 microg/week) followed by a 12-months maintenance phase (1.5 microg/week). Randomly, twenty-four patients added Ni therapy to low-Ni diet and 12 remained with diet alone. All patients were allowed rescue medications (antihistamines and topical steroids). After 4 months, Ni-rich foods were gradually reintroduced. In vitro allergen-driven IL13, IL5 and IFN-gamma release by peripheral blood mononuclear cells was evaluated before and after treatment. Twenty-three patients receiving NiOH and the 12 control patients completed the study. Evaluation of SNAS clinical severity (by VAS and drug consumption) showed a significant difference in favor of NiOH-treated patients compared to controls. Twenty of 23 patients in the NiOH group and none in the control group tolerated Ni-rich food reintroduction. Release of all studied cytokines in culture supernatants was significantly lower after NiOH treatment. In conclusion NiOH is effective in reducing symptoms and drug consumption in SNAS and is able to modulate inflammatory parameters.
authors.affiliation: Departmental Unit of Immunology and Allergology, Internal Medicine, Campi Salentina Hospital, Campi Salentina, Lecce, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Minelli
authors.forename: D
authors.initials: D
authors.lastname: Schiavino
authors.forename: F
authors.initials: F
authors.lastname: Musca
authors.forename: M E
authors.initials: ME
authors.lastname: Bruno
authors.forename: P
authors.initials: P
authors.lastname: Falagiani
authors.forename: G
authors.initials: G
authors.lastname: Mistrello
authors.forename: G
authors.initials: G
authors.lastname: Riva
authors.forename: M
authors.initials: M
authors.lastname: Braga
authors.forename: M C
authors.initials: MC
authors.lastname: Turi
authors.forename: V
authors.initials: V
authors.lastname: Di Rienzo
authors.forename: C
authors.initials: C
authors.lastname: Petrarca
authors.forename: C
authors.initials: C
authors.lastname: Schiavone
authors.forename: M
authors.initials: M
authors.lastname: Di Gioacchino
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D016207:Cytokines / Q000096:biosynthesis*; D003888:Desensitization, Immunologic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009532:Nickel / Q000009:adverse effects*; D013577:Syndrome; D018417:Th1 Cells / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology*
chemical_list: D016207:Cytokines; D009532:Nickel